LSI Medience has validated Pillar’s oncoReveal Essential+ for cfDNA and cfRNA screening, with approximately 2,000 lung cancer patients expected to enter testing over two years.
Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.
Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround